Male infertility and decline in semen quality among men are rising global problems. Intrauterine insemination (IUI) is an effective treatment for mild to moderate forms of male subfertility. The availability of other assisted reproductive techniques (ART) requires actualization of recommendations for IUI use. The paper reviews efficacy of IUI in general and in comparison with IVF treatment, as well as research of sperm analysis thresholds and prognostic factors for IUI and provides clinical recommendations for IUI use in male infertility treatment. The indication for IUI in male factor of infertility should be considered the absence of infectious and inflammatory process in the organs of the reproductive tract, including gonorrhea, chlamydia, mycoplasma genitalium, and trichomonas vaginalis infections, not less than 5 mln progressively motile spermatozoa in the native ejaculate and not less than 1 mln progressively motile spermatozoa in the washed sperm sample, not less than 4% of normal spermatozoa (according to strict criteria) in the native ejaculate; no more than 15—30% of spermatozoa with signs of DNA fragmentation in the native ejaculate; no more than 10—20% of antisperm antibodies on motile sperm after washing. Female critera for IUI are age under 38 years old with ovulation disorders and or cervical factor or idiopathic female infertility, with an ovarian response to the use of clomiphene citrate or letrozole, without infectious and inflammatory process in the pelvic organs; tubal factor infertility; stage II—IV endometriosis; abnormalities of the reproductive system, and somatic and mental illnesses considered as contraindication to planned pregnancy